menu
    • menu
    [{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VRDN-002","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VRDN-002","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Zenas BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Therapeutics \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VRDN-001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Ypsomed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"VRDN-001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Viridian Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Fairmount Funds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"VRDN-001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Fairmount Funds","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Fairmount Funds"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"VRDN-001","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VRDN-003","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VRDN-003","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viridian Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"14","companyTruncated":"Viridian Therapeutics \/ Jefferies"}]

    Find Clinical Drug Pipeline Developments & Deals by Viridian Therapeutics

    Menu

    Viridian Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Prices Upsized Public Offering of Common and Preferred Stock

                            Details : The net proceeds will used to fund its clinical development programs, including VRDN-001 (veligrotug), a differentiated monoclonal antibody targeting IGF-1R for the treatment of thyroid eye disease.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 11, 2024

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viridian Reports Positive Phase 3 Results for Veligrotug in Thyroid Eye Disease

                            Details : VRDN-001 is a differentiated monoclonal antibody targeting IGF-1R, a clinically and commercially validated target for the treatment of thyroid eye disease.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 10, 2024

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Viridian Proposes Public Offering of Common and Preferred Stock

                            Details : The net proceeds will used to fund its clinical development programs, including VRDN-001 (veligrotug), a differentiated monoclonal antibody targeting IGF-1R for the treatment of thyroid eye disease.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Completes Enrollment for VRDN-001 in Chronic Thyroid Eye Disease

                            Details : VRDN-001 is a differentiated monoclonal antibody targeting IGF-1R, a clinically and commercially validated target being investigated for the treatment of thyroid eye disease.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2024

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-003

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viridian Therapeutics: Phase 3 Program for VRDN-003 in Thyroid Eye Disease

                            Details : VRDN-003 is a monoclonal antibody that acts as a full antagonist of IGF-1R, under clinical development for the treatment of Thyroid Eye Disease (TED).

                            Brand Name : VRDN-003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 11, 2024

                            Lead Product(s) : VRDN-003

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

                            Details : Viridian will use proceeds to advance clinical programs, including VRDN-001, a monoclonal antibody targeting IGF-1R for thyroid eye disease.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-003

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Pote...

                            Details : VRDN-003 is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially validated target for TED. It is under phase 1 clinical development for the treatment of Thyroid Eye Disease (TED).

                            Brand Name : VRDN-003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : VRDN-003

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Fairmount Funds

                            Deal Size : $185.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs an...

                            Details : The financing will be used to expand Viridian’s preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases including VRDN-001, for patients with TED.

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Fairmount Funds

                            Deal Size : $185.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Ypsomed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Su...

                            Details : As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidate VRDN-001, for the treatment of thyroid eye disease (TED)...

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Ypsomed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Viridian Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thy...

                            Details : VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED).

                            Brand Name : VRDN-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 10, 2023

                            Lead Product(s) : VRDN-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth